.png){kind=icon}
Return
Sofosbuvir: First Global Approval
.png){kind=icon}
PRE
AI
DOI：10.1007/s40265-014-0179-7.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Sofosbuvir (Solvadi (TM)), a nucleotide analogue hepatitis C virus NS5B polymerase inhibitor, is under development with Gilead Sciences for the once-daily, oral treatment of chronic hepatitis C. Oral sofosbuvir has been approved in the US for the treatment of chronic hepatitis C as a component of a combination antiviral regimen. In addition, the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of sofosbuvir for the treatment of chronic hepatitis C. This article summarizes the milestones in the development of sofosbuvir leading to this first approval for chronic hepatitis C.
Keywords:
TREATMENT-NAIVE PATIENTS
HEPATITIS-C INFECTION
DRUG-DRUG INTERACTION
HIGH SVR RATES
HCV GENOTYPE 1
PLUS RIBAVIRIN
IN-VITRO
GS-7977
HEALTHY
RESISTANCE
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
14.4
Papers:
8.4K
Citations:
2.3W
Organization
Cited Papers
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.png)
LANCET
LANCETIF88.5
PREAI
ShareSaveSofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialLANCET
LANCETIF88.5
PREAI
ShareSaveGlobal epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHEPATOLOGY
OAAI
HEPATOLOGYIF15.8
OAAIShareSaveANALYSIS OF THE KINETICS OF VIRAL DECLINE DURING 14 DAYS OF ADMINISTRATION OF SOFOSBUVIR AND GS-0938
OAAI
OAAIShareSave
View more